Special MRI could spot prostate cancer changes earlier
NCT ID NCT04346225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of MRI that uses a special substance (hyperpolarized pyruvate) to see how active prostate cancer tumors are. Researchers want to know if this scan can find aggressive cancers and show if treatments are working or stopping sooner than standard scans. About 75 adults with advanced prostate cancer will get this extra MRI to help improve future cancer care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2020
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Histologically-confirmed locally advanced or metastatic prostate cancer. Patients with unequivocal clinical evidence supporting diagnosis of prostate cancer who have not had prior biopsy may be considered eligible per judgment of Principal Investigator. 2. Presence of at least one target lesion detected by standard staging scans that, in the judgment of Study Investigators, would be amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging: 1. Soft tissue/visceral organ target lesions must measure at 1 cm in long axis diameter on CT or MRI. 2. Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify). 3. For patients with target lesion in prostate/prostatic bed: i. No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy). ii. No prior local treatment to the selected lesion, or evidence of radiographic progression following prior local therapy to selected lesion. 3. Able and willing to comply with study procedures and provide signed and dated informed consent. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 5. For patients undergoing optional tumor biopsy: 1. No history of bleeding diathesis. 2. Patients on anti-coagulation they must be able to safely stop treatment for purposes of tumor biopsy. Exclusion Criteria: 1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent. 2. Patients unwilling or unable to undergo MR imaging, including patients with contra- indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips. 3. Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MRI. 4. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced prostate carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RE-irradiation for isolated FOCal recurrence of prostate cancer with ultrahypofracted SBRT: the RE-FOCUS study - pushing the boundaries of precision and efficacy
- A sharper eye for cancer: new PET tracer targets hidden tumors
- Can a radioactive tracer help surgeons find hidden prostate cancer?
- Steam therapy vs. surgery: can a less invasive fix help men with blocked urine flow?
- Can smart fluid monitoring improve robotic prostatectomy outcomes?
- Smart blood pressure monitoring may shield kidneys during robotic surgery